New trinuclear nickel(II) complexes as potential topoisomerase I/IIα inhibitors: in vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines

A comprehensive review on anti-inflammatory, antibacterial, anticancer and antifungal properties of several bivalent transition metal complexes

Transition metal complexes have been recognized as possible therapeutic agents, attributed to their special biological actions, including anti-inflammatory, antibacterial, antifungal, and anticancer. The pharmacological perspective connected with Copper (Cu), Cobalt (Co), Nickel (Ni), Manganese (Mn), Palladium (Pd), Zinc (Zn), and Platinum (Pt) metal(II) complexes is comprehensively explored in-depth in this research. The complexes show unique coordination chemistry and modes of action that help interactions with biological targets, including DNA binding, enzyme inhibition, and the formation of reactive oxygen species. All the metal(II) complexes showed notable potential impact in their perspective activity. Conspicuously, Co(II) and Ni(II) complexes show better antibacterial and antifungal action, while Cu(II) and Zn(II) combinations show higher anti-inflammatory activity. While research is constantly investigating alternative metal-based anticancer drugs like Pd(II), which seem to have lowered side effects, Pt(II) complexes especially cisplatin continue to be the benchmark in cancer treatment. Although the possible pharmacological actions are motivating, problems with toxicity and biocompatibility still provide major difficulties, especially in relation to Cd(II) and Hg(II) complexes. Strategies like ligand modification, nanoparticle-based delivery, and prodrug methods are used to increase selectivity and reduce side effects related to metal complexes. This review compiles the most recent developments and continuous research, thereby shedding light on the potential revolutionary power of metal(II) complexes in medical therapy. Understanding their mechanisms and enhancing their safety profiles will help us open the path to creative ideas for addressing some of the most urgent medical issues of today.

Structural insights and in vitro and in vivo anticancer evaluation of dithiocarbamate-based metal complexes against murine lymphoma

Metal-based chemotherapeutics have gained attention due to their ability to interfere with cellular functions. Dithiocarbamate ligands, known for their strong metal-binding properties, have been explored for their potential in anticancer applications. This study aims to synthesize and characterize dithiocarbamate-based Ni(II), Cu(II), and Zn(II) complexes and evaluate their anticancer activity against Dalton's lymphoma (DL) cells. Three dithiocarbamate ligands (1-3) and their corresponding Ni(II), Cu(II), and Zn(II) complexes (1a-c, 2a-c, and 3a-c) were synthesized and characterized using FT-IR, NMR, UV-Vis, and mass spectrometry, and single-crystal X-ray diffraction (SC-XRD). TGA analysis of complexes confirms their thermal stability up to 150 °C and the formation of metal sulfides at elevated temperatures. The in vitro antiproliferative activities of these compounds were assessed using the MTT assay. Apoptosis induction was analyzed via Annexin V-FITC/PI staining and flow cytometry. In vivo studies were conducted on a murine DL tumor model to evaluate therapeutic efficacy and biosafety. SC-XRD confirmed square planar geometries for Ni(II) and Cu(II) complexes, whereas Zn(II) complexes exhibited a tetrahedral geometry. Metal complexes 1c, 2b, and 3c displayed the most potent antiproliferative activity, with 1c exhibiting the lowest IC50 (7.1 μM). Apoptosis analysis indicated that 1c induced 64% apoptosis in DL cells. In vivo studies demonstrated that 1c significantly reduced tumor growth and prolonged survival, with minimal toxicity. The synthesized dithiocarbamate-metal complexes exhibited promising anticancer properties, particularly 1c, which demonstrated superior efficacy in both in vitro and in vivo models. These findings highlight the potential of metal-based dithiocarbamates as novel anticancer agents warranting further preclinical studies.

Novel thiazole-based cyanoacrylamide derivatives: DNA cleavage, DNA/BSA binding properties and their anticancer behaviour against colon and breast cancer cells

A novel series of 2-cyano-3-(pyrazol-4-yl)-N-(thiazol-2-yl)acrylamide derivatives (3a-f) were synthesized using Knoevenagel condensation and characterized using various spectral tools. The weak nuclease activity of compounds (3a-f) against pBR322 plasmid DNA was greatly enhanced by irradiation at 365 nm. Compounds 3b and 3c, incorporating thienyl and pyridyl moieties, respectively, exhibited the utmost nuclease activity in degrading pBR322 plasmid DNA through singlet oxygen and superoxide free radicals' species. Furthermore, compounds 3b and 3c affinities towards calf thymus DNA (CT-DNA) and bovine serum albumin (BSA) were investigated using UV-Vis and fluorescence spectroscopic analysis. They revealed good binding characteristics towards CT-DNA with Kb values of 6.68 × 104 M-1 and 1.19 × 104 M-1 for 3b and 3c, respectively. In addition, compounds 3b and 3c ability to release free radicals on radiation were targeted to be used as cytotoxic compounds in vitro for colon (HCT116) and breast cancer (MDA-MB-231) cells. A significant reduction in the cell viability on illumination at 365 nm was observed, with IC50 values of 23 and 25 µM against HCT116 cells, and 30 and 9 µM against MDA-MB-231 cells for compounds 3b and 3c, respectively. In conclusion, compounds 3b and 3c exhibited remarkable DNA cleavage and cytotoxic activity on illumination at 365 nm which might be associated with free radicals' production in addition to having a good affinity for interacting with CT-DNA and BSA.

Synthesis, Structural Investigations, DNA/BSA Interactions, Molecular Docking Studies, and Anticancer Activity of a New 1,4-Disubstituted 1,2,3-Triazole Derivative

We report herein a new 1,2,3-triazole derivative, namely, 4-((1-(3,4-dichlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-hydroxybenzaldehyde, which was synthesized by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The structure of the compound was analyzed using Fourier transform infrared spectroscopy (FTIR), 1H NMR, 13C NMR, UV-vis, and elemental analyses. Moreover, X-ray crystallography studies demonstrated that the compound adapted a monoclinic crystal system with the P21/c space group. The dominant interactions formed in the crystal packing were found to be hydrogen bonding and van der Waals interactions according to Hirshfeld surface (HS) analysis. The volume of the crystal voids and the percentage of free spaces in the unit cell were calculated as 152.10 Å3 and 9.80%, respectively. The evaluation of energy frameworks showed that stabilization of the compound was dominated by dispersion energy contributions. Both in vitro and in silico investigations on the DNA/bovine serum albumin (BSA) binding activity of the compound showed that the CT-DNA binding activity of the compound was mediated via intercalation and BSA binding activity was mediated via both polar and hydrophobic interactions. The anticancer activity of the compound was also tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using human cell lines including MDA-MB-231, LNCaP, Caco-2, and HEK-293. The compound exhibited more cytotoxic activity than cisplatin and etoposide on Caco-2 cancer cell lines with an IC50 value of 16.63 ± 0.27 μM after 48 h. Annexin V suggests the induction of cell death by apoptosis. Compound 3 significantly increased the loss of mitochondrial membrane potential (MMP) levels in Caco-2 cells, and the reactive oxygen species (ROS) assay proved that compound 3 could induce apoptosis by ROS generation.

Synthesis and characterization of violurate - based Mn(II) and Cu(II) complexes nano-crystallites as DNA-binders and therapeutics agents against SARS-CoV-2 virus

Synthesis and structural characterization of nano crystallites of bis-violurate-based manganese(II) and copper(II) chelates is the subject of the present study. Analytical data and mass spectra as well as thermal analysis determined the molecular formulas of the present metal chelates. Spectroscopic and magnetic measurements assigned the structural formula of the present violurate metal complexes. The spectroscopic and magnetic investigations along with structural analysis results indicated the square planar geometry of both the Mn(II) and Cu(II) complexes. The structural analysis of the synthesized metal complexes was achieved by processing the PXRD data using specialized software Expo 2014. Spectrophotometeric and viscosity measurements showed that violuric acid and its Mn(II) and Cu(II) complexes successfully bind to DNA with intrinsic binding constants K_b from 38.2 × 10⁵ to 26.4 × 10⁶ M⁻¹. The antiviral activity study displayed that the inhibitory concentrations (IC₅₀) of SARS-CoV-2 by violuric acid and its Mn(II) and Cu(II) complexes are 84.01, 39.58 and 44.86 μM respectively. Molecular docking calculations were performed on the SARS-CoV-2 virus protein and the computed binding energy values are −0.8, −3.860 −5.187 and −4.790, kcal/mol for the native ligand, violuric acid and its Mn(II) and Cu(II) complexes respectively. Insights into the relationship between structures of the current compounds and their degree of reactivity are discussed.